Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

  title={Amyloid-$\beta$ protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory},
  author={Ganesh M. Shankar and Shaomin Li and Tapan Mehta and Amaya Garc{\'i}a-Mu{\~n}oz and Nina E. Shepardson and Imelda M. Smith and Francesca Brett and Michael A. Farrell and Michael J. Rowan and Cynthia A. Lemere and Ciaran M. Regan and Dominic M. Walsh and Bernardo L. Sabatini and Dennis J. Selkoe},
  journal={Nature Medicine},
Alzheimer's disease constitutes a rising threat to public health. Despite extensive research in cellular and animal models, identifying the pathogenic agent present in the human brain and showing that it confers key features of Alzheimer's disease has not been achieved. We extracted soluble amyloid-β protein (Aβ) oligomers directly from the cerebral cortex of subjects with Alzheimer's disease. The oligomers potently inhibited long-term potentiation (LTP), enhanced long-term depression (LTD) and… 

Brain amyloid β protein and memory disruption in Alzheimer's disease

Amyloid antibodies and small molecular compounds that reduce brain Aβ levels and block Aβ oligomer formation are capable of reversing synaptic dysfunction and these approaches hold a promising therapeutic potential to rescue memory disruption.

Alzheimer’s Disease Amyloid β-Protein and Synaptic Function

There is growing evidence to support the view that NMDA and possibly nicotinic receptors are critically involved in mediating the disruptive effect of Aβ and that targeting muscarinic receptors can indirectly modulate Aβ’s actions, with particular emphasis on the different roles of glutamatergic and cholinergic mechanisms.

Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers.

The efficacy and toxicity results support a process-specific mechanism of action of molecular tweezers and suggest that these are promising compounds for developing disease-modifying therapy for Alzheimer's disease and related disorders.

A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain

A mechanistic hypothesis for synaptic failure in Alzheimer's disease that can be modified as new knowledge is added and specific therapeutics are developed is synthesized.

Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation

Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

It is concluded that natural dimers isolated from the AD brain are sufficient to potently induce AD-type tau phosphorylation and then neuritic dystrophy, but passive immunotherapy mitigates this.

Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers

The cellular prion protein (PrPC) is identified as an amyloid-β-oligomer receptor by expression cloning, and PrPC-specific pharmaceuticals may have therapeutic potential for Alzheimer’s disease.

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease

A review of the growing body of evidence supporting the implication of soluble Aβo on the induction of neuronal hyperactivity in AD animal models, in vitro, and in humans and an outlook on the impact of hyperactivity for the development of disease-modifying interventions at the onset of AD.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

It is proposed that Aβ*56 may play a pathogenic role very early in the pathogenesis of Alzheimer's disease, as well as three amyloid-β oligomers previously described in mouse models, which are studied in several mouse models and systematically in humans.

Amyloid-β as a modulator of synaptic plasticity.

This review examines the long-awaited functional impact of Aβ on synaptic plasticity and suggests a distinction between age effects on the target response in contrast to the assembly state or the accumulation of the peptide.



Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

The biochemical isolation of discrete amyloid-β moieties with pathophysiological properties sets the stage for a new approach to studying the molecular mechanisms of cognitive impairment in Alzheimer disease and related neurodegenerative disorders.

Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

It is reported that untreated ex vivo human CSF that contains Aβ dimers rapidly inhibits hippocampal long-term potentiation in vivo and that acute systemic infusion of an anti-Aβ monoclonal antibody can prevent this disruption of synaptic plasticity.

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

It is reported that natural oligomers of human Aβ are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically.

A specific amyloid-β protein assembly in the brain impairs memory

It is found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which is proposed to be Aβ*56 (Aβ star 56), which may contribute to cognitive deficits associated with Alzheimer's disease.

Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway

It is concluded that soluble, low-n oligomers of human Aβ trigger synapse loss that can be reversed by therapeutic agents and provides a quantitative cellular model for elucidating the molecular basis of Aβ-induced neuronal dysfunction.

A specific amyloid-beta protein assembly in the brain impairs memory.

It is found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-beta assembly, which is proposed to be Abeta*56 (Abeta star 56), which may contribute to cognitive deficits associated with Alzheimer's disease.

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

It is concluded that the pathogenically critical process of Abeta oligomers, principally dimers, in primary human neurons and in neuronal and nonneural cell lines begins intraneuronally.

Soluble Amyloid b Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

Investigation revealed that A b 40, whether in soluble or insoluble form, was a particularly useful measure for classifying ND, HPC, and AD patients compared with A b 42, and concentrations of soluble A b clearly distinguished HPC from AD patients and were a strong inverse correlate of synapse loss.

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

The observed disruption of dendritic spines links ADDLs to a major facet of AD pathology, providing strong evidence that AD DLs in AD brain cause neuropil damage believed to underlie dementia.